Galderma Group (SWX:GALD) - Stock Price, News & Analysis

GALD Stock Overview

Galderma Group AG operates as a dermatology company.

GALD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Has not reported any financial data

Galderma Group AG Competitors

Sandoz Group

SWX:SDZ

CHF12.9b

Dottikon ES Holding

SWX:DESN

CHF3.2b

Roche Holding

SWX:ROG

CHF178.2b

Novartis

SWX:NOVN

CHF182.6b

Price History & Performance

Summary of all time highs, changes and price drops for Galderma Group
Historical stock prices
Current Share Price	CHF66.79
52 Week High	CHF69.11
52 Week Low	CHF60.00
Beta	0
1 Month Change	5.43%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	4.36%

Recent updates

Shareholder Returns

	GALD	CH Pharmaceuticals	CH Market
7D	-0.3%	0.01%	0.1%
1Y	n/a	8.7%	-3.2%

Return vs Industry: Insufficient data to determine how GALD performed against the Swiss Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GALD performed against the Swiss Market.

Price Volatility

Is GALD's price volatile compared to industry and market?
GALD volatility
GALD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	3.0%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.2%
10% least volatile stocks in CH Market	2.0%

Stable Share Price: GALD has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GALD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	n/a	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company. It delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market though injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
GALD fundamental statistics
Market cap	CHF15.89b
Earnings (TTM)	CHF0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is GALD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GALD income statement (TTM)
Revenue	CHF0
Cost of Revenue	CHF0
Gross Profit	CHF0
Other Expenses	CHF0
Earnings	CHF0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did GALD perform over the long term?

See historical performance and comparison

Galderma Group SWX:GALD Stock Report